Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study Journal Article
| Authors: | Praiss, A. M.; Hirani, R.; Zhou, Q.; Iasonos, A.; Sonoda, Y.; Abu-Rustum, N. R.; Leitao, M. M. Jr; Long Roche, K.; Broach, V.; Gardner, G. J.; Chi, D. S.; Zivanovic, O. |
| Article Title: | Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study |
| Abstract: | Objective: To assess the impact of short-term postoperative complications on oncologic outcomes for patients with epithelial ovarian cancer undergoing primary cytoreductive surgery (PCS) or interval cytoreductive surgery (ICS) with intestinal resection. Methods: A retrospective chart review was performed for patients with ovarian cancer who underwent PCS or ICS with at least one intestinal resection at our institution from 1/1/2015 to 12/31/2020. Progression-free survival (PFS) and overall survival (OS) were analyzed for the PCS and ICS cohorts separately. Short-term complications within 30 days of surgery (surgical secondary events [SSEs]) were graded by a validated institutional SSE system. Results: Among 437 patients who underwent intestinal resections during PCS (n = 289) or ICS (n = 148), 183 (42%) had one, 180 (41%) had two, and 74 (17%) had three intestinal resections. Six (1.4%) of 437 patients experienced an anastomotic leak postoperatively. There were no perioperative deaths. There was no difference in PFS and OS for patients who underwent PCS with any SSE vs. no SSE within 30 days of surgery (HR, 1.05; 95% CI: 0.76–1.47; p = 0.75 and HR, 0.79; 95% CI: 0.49–1.26; p = 0.32, respectively). There was no difference in PFS and OS for patients who underwent ICS with any SSE vs. no SSE within 30 days of surgery (HR, 1.43; 95% CI: 0.99–2.07; p = 0.055 and HR. 1.18; 95% CI: 0.72–1.93; p = 0.52, respectively. Conclusion: Short-term postoperative morbidity for patients who underwent intestinal surgery during primary surgical management for advanced ovarian cancer did not impact oncologic outcomes. © 2023 |
| Keywords: | adult; cancer chemotherapy; controlled study; aged; retrospective studies; major clinical study; overall survival; clinical feature; bevacizumab; advanced cancer; preoperative evaluation; ovarian cancer; cytoreductive surgery; ovarian neoplasms; progression free survival; morbidity; cohort analysis; medical record review; retrospective study; histology; postoperative complication; length of stay; albumin; minimal residual disease; ovary tumor; reoperation; ovary carcinoma; intestine resection; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; intestine perforation; appendectomy; ileus; wound complication; small intestine obstruction; anastomosis leakage; anastomotic leak; primary cytoreductive surgery; postoperative morbidity; urinary tract disease; abdominal infection; interval cytoreductive surgery; ostomy; humans; human; female; article; cytoreduction surgical procedures; carcinoma, ovarian epithelial; intestinal resection |
| Journal Title: | Gynecologic Oncology |
| Volume: | 179 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-12-01 |
| Start Page: | 169 |
| End Page: | 179 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2023.10.013 |
| PUBMED: | 37992548 |
| PROVIDER: | scopus |
| PMCID: | PMC11332218 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Oliver Zivanovic -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work